Immunization

Experts forecast a potential resurgence of measles and other vaccine-preventable diseases in the U.S. due to declining vaccination rates.

According to phase 3 trial results, Pfizer-BioNTech’s LP.8.1-adapted COVID-19 vaccine demonstrated significant immune responses in older adults and individuals at high risk for severe COVID-19.

Florida's Surgeon General's plan to eliminate school vaccine mandates raises concerns about measles outbreaks and declining vaccination rates.

The 21-valent pneumococcal conjugate vaccine (PCV21) elicited favorable immunogenicity and safety in infants and toddlers who were coadministered common pediatric vaccines, such as the measles-mumps-rubella vaccine.

Research reveals how aging impacts flu severity in older adults, highlighting the need for enhanced vaccines and new therapeutic strategies.

New findings suggest high-dose influenza vaccines offer better protection against the flu and reduce cardiac complications in older adults.

A single dose of an RSV vaccine significantly reduces hospitalization risk for older adults, offering protection for 2 seasons against severe infections.

Vaccination is vital for adults with heart disease to prevent severe respiratory illnesses like RSV, influenza, and COVID-19, enhancing overall health outcomes.

Greater effectiveness was seen in children 1 year and older.

Allison Hill, PharmD, RPh explains how pharmacists’ accessibility and trusted relationships make them key to combatting vaccine hesitancy.

Alyssa Modic, PharmD, discusses the evolving role of pharmacists in adult immunizations and strategies to improve respiratory syncytial virus (RSV) vaccine education and uptake.

FluMist Home, the first at-home nasal spray flu vaccine, is now available for direct delivery to patients in 34 US states.

Allison Hill, PharmD, RPh, emphasized that pharmacists must stay updated on ACIP and state-level guidance following HHS’s changes to COVID-19 vaccine authorizations.

The FDA's approvals follow new COVID-19 guidance announced by the commissioner of the agency in May 2025, focusing future approvals on older adults.

The FDA suspended the biologics license for Ixchiq, the first approved chikungunya vaccine, after reports of serious adverse events and fatalities.

A novel shingles vaccine candidate demonstrated positive top-line results of antibody and CD4⁺ T-cell vaccine responses.

Alyssa Modic, PharmD, explains how pharmacists can clarify pneumococcal vaccine schedules, manage coadministration decisions, and reframe vaccination conversations for patients.

Patients in an outpatient oncology unit expressed willingness to receive a pneumococcal or influenza vaccine from a pharmacist if offered.

Alyssa Modic, PharmD, emphasizes the importance of evidence-based advocacy and continuous education as vaccine recommendations evolve.

Samantha Picking, PharmD, senior director of immunizations at Walgreens, shares how pharmacy teams are addressing vaccine misinformation, managing coadministration, and supporting test-to-treat services during a complex respiratory season.

RSVpreF was well tolerated in nonpregnant and pregnant individuals aged 18 years and older.

The AAP unveiled its 2025 immunization schedule, challenging CDC guidelines and emphasizing evidence-based vaccine recommendations for children's health.

Samantha Picking, PharmD, senior director of immunizations at Walgreens, discusses staffing strategies, digital tools, and operational improvements designed to streamline flu vaccination services during the upcoming respiratory season.

Case highlights the importance of careful cocumentation.

Many adults remain unaware of HPV's cancer risks, highlighting the urgent need for increased awareness.

RSV vaccination rates among older adults remain low despite new vaccines, highlighting disparities in uptake and the need for targeted outreach.

Pharmacists play a crucial role in improving vaccination rates among patients with cancer, addressing barriers, and enhancing patient education in oncology care.

In a phase 3 trial, V116 demonstrated significant immunogenicity in older adults who had not before received a pneumococcal vaccination.

Older adults in the United States continue to be burdened with disproportionate rates of community-acquired pneumonia hospitalizations, including due to serotypes covered in the recently approved V116 vaccine.